# Immunophenotyping Profiling in Patients With Primary Nephrotic Syndrome

> **NCT07702981** · — · COMPLETED · sponsor: **University Hospital, Ioannina** · enrollment: 40 (actual)

## Conditions studied

- Membranous Nephropathy
- Minimal Change Disease (MCD)
- Focal Segmental Glomerulosclerosis (FSGS)

## Interventions

- **DRUG:** Rituximab (MABTHERA® or RITUXAN®).
- **DRUG:** Corticosteroids (CS)
- **DRUG:** Corticosteroids (CS)

## Key facts

- **NCT ID:** NCT07702981
- **Lead sponsor:** University Hospital, Ioannina
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2023-06-01
- **Primary completion:** 2025-11-01
- **Final completion:** 2026-02-01
- **Target enrollment:** 40 (ACTUAL)
- **Last updated:** 2026-07-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07702981

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07702981, "Immunophenotyping Profiling in Patients With Primary Nephrotic Syndrome". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07702981. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*